Literature DB >> 25612900

Evaluation of mold exposure in cystic fibrosis patients' dwellings and allergic bronchopulmonary risk.

Steffi Rocchi1, Bénédicte Richaud-Thiriez2, Coralie Barrera1, Frédéric Grenouillet1, Jean-Charles Dalphin3, Laurence Millon1, Gabriel Reboux4.   

Abstract

Very few studies have been conducted on cystic fibrosis (CF) patients' exposure to the indoor environment and, to our knowledge, there are no studies dealing with the link between specific fungal environmental exposure at home and fungal colonization resulting in allergic bronchopulmonary aspergillosis (ABPA). Fungal exposure of CF adult patients with ABPA (n=4) with fungal sensitization (n=7) and with no ABPA (n=5) was assessed in 16 homes by dust sampling with electrostatic dust fall collectors (EDCs). Aspergillus fumigatus was specifically quantified by real-time quantitative polymerase chain reactions (qPCRs), and A. fumigatus DNA concentrations were significantly higher in homes of ABPA patients (p<0.001). Results indicate that indoor fungal contamination could be a factor favoring ABPA and suggest that environmental surveys could help in preventing fungal risk in CF patients.
Copyright © 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Allergic bronchopulmonary aspergillosis (ABPA); Aspergillus fumigatus; Cystic fibrosis (CF); Dwellings; Real-time quantitative polymerase chain reactions (qPCRs)

Mesh:

Substances:

Year:  2015        PMID: 25612900     DOI: 10.1016/j.jcf.2015.01.003

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  6 in total

Review 1.  Proteomics as a Tool to Identify New Targets Against Aspergillus and Scedosporium in the Context of Cystic Fibrosis.

Authors:  Andoni Ramirez-Garcia; Aize Pellon; Idoia Buldain; Aitziber Antoran; Aitana Arbizu-Delgado; Xabier Guruceaga; Aitor Rementeria; Fernando L Hernando
Journal:  Mycopathologia       Date:  2017-05-08       Impact factor: 2.574

2.  New Commercially Available IgG Kits and Time-Resolved Fluorometric IgE Assay for Diagnosis of Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis.

Authors:  Coralie Barrera; Bénédicte Richaud-Thiriez; Steffi Rocchi; Bénédicte Rognon; Sandrine Roussel; Frédéric Grenouillet; Audrey Laboissière; Jean-Charles Dalphin; Gabriel Reboux; Laurence Millon
Journal:  Clin Vaccine Immunol       Date:  2015-12-23

Review 3.  Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies.

Authors:  Gabriela R Oates; Michael S Schechter
Journal:  Expert Rev Respir Med       Date:  2022-06-23       Impact factor: 4.300

Review 4.  Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy.

Authors:  Pierre-Régis Burgel; André Paugam; Dominique Hubert; Clémence Martin
Journal:  Infect Drug Resist       Date:  2016-09-20       Impact factor: 4.003

5.  Comparative Analysis of Clinical Parameters and Sputum Biomarkers in Establishing the Relevance of Filamentous Fungi in Cystic Fibrosis.

Authors:  Deepa Patel; Keith Chester Dacanay; Catherine H Pashley; Erol A Gaillard
Journal:  Front Cell Infect Microbiol       Date:  2021-01-22       Impact factor: 5.293

Review 6.  Influences of environmental exposures on individuals living with cystic fibrosis.

Authors:  Rhonda Szczesniak; Jessica L Rice; Cole Brokamp; Patrick Ryan; Teresa Pestian; Yizhao Ni; Eleni-Rosalina Andrinopoulou; Ruth H Keogh; Emrah Gecili; Rui Huang; John P Clancy; Joseph M Collaco
Journal:  Expert Rev Respir Med       Date:  2020-04-26       Impact factor: 3.772

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.